{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:57:11Z","timestamp":1782903431696,"version":"3.54.5"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","funder":[{"name":"Innovation Capability Support Program of Shaanxi","award":["Program No. 2023-CX-PT-43"],"award-info":[{"award-number":["Program No. 2023-CX-PT-43"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Cytomegalovirus (CMV) infection is associated with higher non-relapse mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). But the preferred drug for preventing cytomegalovirus infection is still controversial. We evaluate the efficacy, safety, and cost-effectiveness of antiviral agents based on the most recent studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>A pairwise and network meta-analysis was conducted to obtain direct and indirect evidence of antivirals. The cost of allo-HSCT recipients in a teaching hospital was collected, and a cost-effectiveness analysis using a decision tree combined with Markov model was completed from the perspective of allo-HSCT recipients over a lifetime horizon.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>A total of 19 RCTs involving 3565 patients (8 antivirals) were included. In the network meta-analysis, relative to placebo, letermovir, valacyclovir, and ganciclovir significantly reduced CMV infection incidence; ganciclovir significantly reduced CMV disease incidence; ganciclovir significantly increased the incidence of serious adverse event; none of antivirals significantly reduced all-cause mortality. Based on meta-analysis and Chinese medical data, the incremental cost-effectiveness ratios (ICER) per quality-adjusted life year (QALY) saved for maribavir, acyclovir, valacyclovir, ganciclovir, and letermovir relative to placebo corresponded to US$216 635.70, US$11 590.20, US$11 816.40, US$13 049.90, and US$12 189.40, respectively. One-way sensitivity analysis showed the most influential parameter was discount rate. The probabilistic sensitivity analysis indicated a 53.0% probability of letermovir producing an ICER below the willingness-to-pay threshold of US$38 824.23\/QALY. The scenario analysis demonstrated prophylaxis with letermovir is considered cost-effective in the United States.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Currently, letermovir is an effective and well-tolerated treatment for preventing CMV infection, and it might be a cost-effective choice in allo-HSCT recipients in China.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000004856","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T05:00:26Z","timestamp":1701752426000},"page":"1021-1032","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy, Safety, and Cost-effectiveness Analysis of Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients"],"prefix":"10.1097","volume":"108","author":[{"given":"Yulan","family":"Qiu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luting","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanfang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taotao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1016\/S2352-3026(22)00293-9","article-title":"Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions.","volume":"9","author":"Chang","year":"2022","journal-title":"Lancet Haematol"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years.","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from the Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update.","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.cmi.2021.10.008","article-title":"The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a systematic review and meta-analysis.","volume":"28","author":"Chuleerarux","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jcv.2015.12.003","article-title":"Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus.","volume":"75","author":"Chen","year":"2016","journal-title":"J Clin Virol"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"8497","DOI":"10.1002\/cam4.4353","article-title":"Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: a single-center retrospective study.","volume":"10","author":"Lv","year":"2021","journal-title":"Cancer Med"},{"key":"R8-20250604","first-page":"6551","article-title":"Risk factors for cytomegalovirus infection after allogeneic hematopoietic cell transplantation in malignancies: proposal for classification.","volume":"37","author":"Dziedzic","year":"2017","journal-title":"Anticancer Res"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-017-0180-z","article-title":"Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation.","volume":"7","author":"Styczynski","year":"2018","journal-title":"Infect Dis Ther"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients.","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American Society for Transplantation and Cellular Therapy Series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation.","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R13-20250604","first-page":"617","article-title":"The Chinese consensus on the management of cytomegalovirus infection in allogeneic.","volume":"43","year":"2022","journal-title":"Chin J Hematol"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"CMV viral load and mortality after hematopoietic cell transplantation: a cohort study in the era of preemptive therapy.","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41409-022-01863-8","article-title":"New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the Infectious Diseases Working Pary of EBMT.","volume":"58","author":"Cesaro","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force.","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0140-6736(94)91835-X","article-title":"Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation European Acyclovir for CMV Prophylaxis Study Group.","volume":"343","author":"Prentice","year":"1994","journal-title":"Lancet"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.bmt.1700498","article-title":"Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection the European Acyclovir for CMV Prophylaxis Study Group.","volume":"19","author":"Prentice","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0140-6736(83)92248-1","article-title":"Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir.","volume":"2","author":"Gluckman","year":"1983","journal-title":"Lancet"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/bjc.1989.88","article-title":"The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation.","volume":"59","author":"Selby","year":"1989","journal-title":"Br J Cancer"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199112053252303","article-title":"Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.","volume":"325","author":"Goodrich","year":"1991","journal-title":"N Engl J Med"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","article-title":"Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant.","volume":"118","author":"Goodrich","year":"1993","journal-title":"Ann Intern Med"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-118-3-199302010-00004","article-title":"Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial.","volume":"118","author":"Winston","year":"1993","journal-title":"Ann Intern Med"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.bmt.1703770","article-title":"Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.","volume":"30","author":"Burns","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V99.8.3050","article-title":"Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.","volume":"99","author":"Ljungman","year":"2002","journal-title":"Blood"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1086\/367836","article-title":"Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.","volume":"36","author":"Winston","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2005-09-3624","article-title":"Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation\u2014a randomized double-blind placebo-controlled study.","volume":"107","author":"Boeckh","year":"2006","journal-title":"Blood"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Intern Med"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation.","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation.","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R37-20250604","first-page":"618","article-title":"A single center, prospective randomized controlled study of ganciclovir and foscarnet in the prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.","volume":"33","author":"Tan","year":"2020","journal-title":"J Clin Hematol (China)"},{"key":"R38-20250604","first-page":"1535","article-title":"Analysis of the clinical effect of foscarnet sodium in the prevention of CMV infection after allo-HSCT.","volume":"32","author":"Zhao","year":"2021","journal-title":"Mod Diagn Treat"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.bbmt.2018.05.017","article-title":"Comparative efficacy and safety of different antiviral agents for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.","volume":"24","author":"Gagelmann","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/bloodadvances.2018016493","article-title":"Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation.","volume":"2","author":"Chen","year":"2018","journal-title":"Blood Adv"},{"key":"R41-20250604","first-page":"238","article-title":"Global quality of life in patients who have undergone the hematopoietic stem cell transplantation: finding from transversal and retrospective study.","volume":"27","author":"Slovacek","year":"2005","journal-title":"Exp Oncol"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev-med-042921-124739","article-title":"Cytomegalovirus therapy: role of letermovir in prophylaxis and treatment in transplant recipients.","volume":"74","author":"Saullo","year":"2023","journal-title":"Annu Rev Med"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cmi.2019.09.003","article-title":"Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis.","volume":"26","author":"Beyar-Katz","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ejh.12324","article-title":"Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study.","volume":"93","author":"Leunis","year":"2014","journal-title":"Eur J Haematol"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2217\/fon-2018-0842","article-title":"A real-world, cross-sectional, community survey of symptoms and health-related quality of life of adults with acute myeloid leukemia.","volume":"15","author":"Mamolo","year":"2019","journal-title":"Future Oncol"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/jha2.62","article-title":"Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada.","volume":"1","author":"Cressman","year":"2020","journal-title":"EJHaem"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1007\/s00277-021-04654-1","article-title":"The anemia-independent impact of myelodysplastic syndromes on health-related quality of life.","volume":"100","author":"Wouters","year":"2021","journal-title":"Ann Hematol"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1007\/s00520-020-05774-6","article-title":"Health-related quality of life measured using EQ-5D in patients with lymphomas.","volume":"29","author":"Xu","year":"2021","journal-title":"Support Care Cancer"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s11136-020-02644-w","article-title":"A head-to-head comparison of measurement properties of the EQ-5D-3L and EQ-5D-5L in acute myeloid leukemia patients.","volume":"30","author":"Yu","year":"2021","journal-title":"Qual Life Res"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2147\/IDR.S196282","article-title":"Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy.","volume":"12","author":"Restelli","year":"2019","journal-title":"Infect Drug Resist"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1080\/13696998.2020.1843321","article-title":"Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong.","volume":"23","author":"Chan","year":"2020","journal-title":"J Med Econ"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1002\/jmv.26462","article-title":"Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective.","volume":"93","author":"Alsumali","year":"2021","journal-title":"J Med Virol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:10:39Z","timestamp":1749060639000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004856","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,5]]}}}